The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 20, 2018
Filed:
Mar. 23, 2016
Novartis Ag, Basel, CH;
Nicole Buschmann, Basel, CH;
Robin Alec Fairhurst, Basel, CH;
Jorge Garcia Fortanet, Wilmington, MA (US);
Pascal Furet, Thann, FR;
Diana Graus Porta, Basel, CH;
Nafeeza Hafeez, Brookline, MA (US);
Bo Han, Shanghai, CN;
Thomas Knoepfel, Rheinfelden, CH;
Matthew J. LaMarche, Reading, MA (US);
Catherine Leblanc, Basel, CH;
Lv Liao, Shanghai, CN;
Robert Mah, Muttenz, CH;
Dale Porter, Cambridge, MA (US);
Can Wang, Suzhou, CN;
Markus Wartmann, Riehen, CH;
Jing Xiong, Shanghai, CN;
Xianglin Zhao, Shanghai, CN;
Novartis AG, Basel, CH;
Abstract
A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.